Search Results - "Tausch, E"

ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia—update on methodological approaches and results interpretation by Malcikova, J., Tausch, E., Rossi, D., Sutton, L. A., Soussi, T., Zenz, T., Kater, A. P., Niemann, C. U., Gonzalez, D., Davi, F., Gonzalez Diaz, M., Moreno, C., Gaidano, G., Stamatopoulos, K., Rosenquist, R., Stilgenbauer, S., Ghia, P., Pospisilova, S.

“…In chronic lymphocytic leukemia (CLL), TP53 gene defects, due to deletion of the 17p13 locus and/or mutation(s) within the TP53 gene, are associated with…”
Get full text

Richter transformation in chronic lymphocytic leukemia (CLL)—a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials by Al-Sawaf, O., Robrecht, S., Bahlo, J., Fink, A. M., Cramer, P., v Tresckow, J., Lange, E., Kiehl, M., Dreyling, M., Ritgen, M., Dürig, J., Tausch, E., Schneider, C., Stilgenbauer, S., Wendtner, C. M., Fischer, K., Goede, Hallek, M., Eichhorst, B.

“…Richter transformation (RT) is defined as development of aggressive lymphoma in patients (pts) with CLL. The incidence rates of RT among pts with CLL range…”
Get full text

Recurrent mutations refine prognosis in chronic lymphocytic leukemia by Baliakas, P, Hadzidimitriou, A, Sutton, L-A, Rossi, D, Minga, E, Villamor, N, Larrayoz, M, Kminkova, J, Agathangelidis, A, Davis, Z, Tausch, E, Stalika, E, Kantorova, B, Mansouri, L, Scarfò, L, Cortese, D, Navrkalova, V, Rose-Zerilli, M J J, Smedby, K E, Juliusson, G, Anagnostopoulos, A, Makris, A M, Navarro, A, Delgado, J, Oscier, D, Belessi, C, Stilgenbauer, S, Ghia, P, Pospisilova, S, Gaidano, G, Campo, E, Strefford, J C, Stamatopoulos, K, Rosenquist, R

“…Through the European Research Initiative on chronic lymphocytic leukemia (CLL) (ERIC), we screened 3490 patients with CLL for mutations within the NOTCH1 ( n…”
Get full text

Genomic profiling of Acute lymphoblastic leukemia in ataxia telangiectasia patients reveals tight link between ATM mutations and chromothripsis by Ratnaparkhe, M, Hlevnjak, M, Kolb, T, Jauch, A, Maass, K K, Devens, F, Rode, A, Hovestadt, V, Korshunov, A, Pastorczak, A, Mlynarski, W, Sungalee, S, Korbel, J, Hoell, J, Fischer, U, Milde, T, Kramm, C, Nathrath, M, Chrzanowska, K, Tausch, E, Takagi, M, Taga, T, Constantini, S, Loeffen, J, Meijerink, J, Zielen, S, Gohring, G, Schlegelberger, B, Maass, E, Siebert, R, Kunz, J, Kulozik, A E, Worst, B, Jones, D T, Pfister, S M, Zapatka, M, Lichter, P, Ernst, A

“…Recent developments in sequencing technologies led to the discovery of a novel form of genomic instability, termed chromothripsis. This catastrophic genomic…”
Get full text

Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemia by Parker, H, Rose-Zerilli, M J J, Larrayoz, M, Clifford, R, Edelmann, J, Blakemore, S, Gibson, J, Wang, J, Ljungström, V, Wojdacz, T K, Chaplin, T, Roghanian, A, Davis, Z, Parker, A, Tausch, E, Ntoufa, S, Ramos, S, Robbe, P, Alsolami, R, Steele, A J, Packham, G, Rodríguez-Vicente, A E, Brown, L, McNicholl, F, Forconi, F, Pettitt, A, Hillmen, P, Dyer, M, Cragg, M S, Chelala, C, Oakes, C C, Rosenquist, R, Stamatopoulos, K, Stilgenbauer, S, Knight, S, Schuh, A, Oscier, D G, Strefford, J C

“…Histone methyltransferases (HMTs) are important epigenetic regulators of gene transcription and are disrupted at the genomic level in a spectrum of human…”
Get full text

Characterization of the genetic and epigenetic landscape of B‐cell neoplasms with IG::BCL3‐translocation by Drewes, C., López, C., Okeke, N., Hillebrecht, S., Schütz, P., Fischer, A., Mottok, A., Bens, S., Schneider, C., Stilgenbauer, S., Tausch, E., Siebert, R.

Get full text

Ethyl-Zinc(II)-Cation Equivalents: Synthesis and Hydroamination Catalysis by Petersen, T. O., Tausch, E., Schaefer, J., Scherer, H., Roesky, P. W., Krossing, I.

“…Ion‐like ethylzinc(II) compounds with weakly coordinating aluminates [Al(ORF)4]− and [(RFO)3Al‐F‐Al(ORF)3]− (RF=C(CF3)3) were synthesized in a one‐pot reaction…”
Get full text

Deep learning can predict presence of TP53 aberrations and IGHV mutational status from peripheral blood smears of chronic lymphocytic leukemia by Pachong, S. Mebwe, Robrecht, S., Ligtvoet, R., Tausch, E., Schneider, C., Fürstenau, M., Tresckow, J., Huber, H., Stilgenbauer, S., Cramer, P., Eichhorst, B., Kreuzer, K., Hallek, M., Fischer, K., Al‐Sawaf, O.

Get full text

Rare germline variants in ATM are associated with chronic lymphocytic leukemia by Tiao, G, Improgo, M R, Kasar, S, Poh, W, Kamburov, A, Landau, D-A, Tausch, E, Taylor-Weiner, A, Cibulskis, C, Bahl, S, Fernandes, S M, Hoang, K, Rheinbay, E, Kim, H T, Bahlo, J, Robrecht, S, Fischer, K, Hallek, M, Gabriel, S, Lander, E S, Stilgenbauer, S, Wu, C J, Kiezun, A, Getz, G, Brown, J R

Get full text

A PHASE 3 TRIAL OF ACALABRUTINIB, OBINUTUZUMAB AND VENETOCLAX COMPARED TO OBINUTUZUMAB AND VENETOCLAX IN PATIENTS WITH HIGH RISK CHRONIC LYMPHOCYTIC LEUKEMIA by Kutsch, N., Fink, A. M., Robrecht, S., Tausch, E., Schneider, C., Dierks, C., Wendtner, C., Meyer, R., Gaska, T., Chakupurakal, G., Jentsch‐Ullrich, K., Steiniger, H., Schwaner, I., Neumann, C., Fischer, K., Kreuzer, K., Ritgen, M., Stilgenbauer, S., Hallek, M., Eichhorst, B.

Get full text

Safety of acalabrutinib treatment in very old (≥80 y) and/or frail patients with chronic lymphocytic leukemia ‐ interim safety analysis of the ongoing phase II CLL‐Frail trial by Simon, F., Ligtvoet, R., Nösslinger, T., Bohn, J., Tresckow, J., Liersch, R., Gaska, T., Jentsch‐Ullrich, K., Koenigsmann, M., Wolff, T., Schwaner, I., Wolf, D., Schneider, C., Tausch, E., Stilgenbauer, S., Kreuzer, K., Robrecht, S., Fink, A., Fürstenau, M., Fischer, K., Goede, V., Hallek, M., Eichhorst, B.

Get full text

VENETOCLAX‐OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 6‐YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY by Al‐Sawaf, O., Robrecht, S., Zhang, C., Olivieri, S., Chang, Y. M., Fink, A. M., Tausch, E., Schneider, C., Ritgen, M., Kreuzer, K., Sivcheva, L., Niemann, C., Schwarer, A., Loscertales, J., Weinkove, R., Strumberg, D., Kilfoyle, A., Runkel, E. D., Eichhorst, B., Stilgenbauer, S., Jiang, Y., Hallek, M., Fischer, K.

Get full text

IBRUTINIB VERSUS PLACEBO IN PATIENTS WITH ASYMPTOMATIC, TREATMENT‐NAïVE EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): FINAL RESULTS OF THE CLL12 TRIAL by Langerbeins, P., Robrecht, S., Nieper, P., Cramer, P., Fürstenau, M., Al‐Sawaf, O., Fink, A., Kreuzer, K., Vehling‐Kaiser, U., Tausch, E., Schneider, C., Müller, L., Schlag, R., Freier, W., Gaska, T., Balser, C., Reiser, M., Stauch, M., Zahn, M., Dörfel, S., Eckart, M. J., Staib, P., Behlendorf, T., Hensel, M., Hebarth, H., Klaproth, H., Block, A., Liersch, R., Hauch, U., Heinrich, B., Wendtner, C., Fischer, K., Stilgenbauer, S., Eichhorst, B., Hallek, M.

Get full text

A CONTINUOUS INDIVIDUALIZED RISK INDEX FOR REFINED OUTCOME PREDICTION AFTER TARGETED THERAPY FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CIRI‐CLL) by Al‐Sawaf, O., Esfahani, M. S., Zhang, C., Tausch, E., Schilhabel, A., Eichhorst, B., Stilgenbauer, S., Hallek, M., Alizadeh, A. A., Kurtz, D. M., Fischer, K.

Get full text

Frequent evolution of copy number alterations in CLL following first-line treatment with FC(R) is enriched with TP53 alterations: results from the CLL8 trial by Edelmann, J, Tausch, E, Landau, D A, Robrecht, S, Bahlo, J, Fischer, K, Fink, A M, Bloehdorn, J, Holzmann, K, Böttcher, S, Werner, L, Kneba, M, Gribben, J G, Neuberg, D S, Wu, C J, Hallek, M, Döhner, H, Stilgenbauer, S

Get full text

THE CLL‐RT1 TRIAL: A MULTICENTER PHASE‐2 TRIAL OF ZANUBRUTINIB, A BTK INHIBITOR, PLUS TISLELIZUMAB, A PD‐1 INHIBITOR, FOR PATIENTS WITH RICHTER TRANSFORMATION by Al‐Sawaf, O., Robrecht, S., Stumpf, J., Fink, A.‐M., Ritgen, M., Johansson, P., Tausch, E., Hoechstetter, M., Staber, P., Jäger, U., Niemann, C. U., Pallasch, C., Kreuzer, K.‐A., Stilgenbauer, S., Fischer, K., Wendtner, C., Hallek, M., Eichhorst, B.

Get full text

VENETOCLAX‐OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 4‐YEAR FOLLOW‐UP ANALYSIS OF THE RANDOMIZED CLL14 STUDY by Al‐Sawaf, O., Zhang, C., Robrecht, S., Tandon, M., Panchal, A., Fink, A.‐M., Tausch, E., Ritgen, M., Kreuzer, K.‐A., Kim, S., Wendtner, C., Eichhorst, B., Stilgenbauer, S., Jiang, Y., Hallek, M., Fischer, K.

Get full text

Intrinsic and chemo-sensitizing activity of SMAC-mimetics on high-risk childhood acute lymphoblastic leukemia by Schirmer, M, Trentin, L, Queudeville, M, Seyfried, F, Demir, S, Tausch, E, Stilgenbauer, S, Eckhoff, S M, Meyer, L H, Debatin, K-M

“…SMAC-mimetics represent a targeted therapy approach to overcome apoptosis resistance in many tumors. Here, we investigated the efficacy of the SMAC-mimetic BV6…”
Get full text

Innovation in the prognostication of chronic lymphocytic leukemia: how far beyond TP53 gene analysis can we go? by Pospisilova, Sarka, Sutton, Lesley-Ann, Malcikova, Jitka, Tausch, Eugen, Rossi, Davide, Montserrat, Emili, Moreno, Carol, Stamatopoulos, Kostas, Gaidano, Gianluca, Rosenquist, Richard, Ghia, Paolo

Get full text

S148: VENETOCLAX‐OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 5‐YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY by Al‐Sawaf, O., Zhang, C., Robrecht, S., Kotak, A., Chang, N., Fink, A.‐M., Tausch, E., Schneider, C., Ritgen, M., Kreuzer, K.‐A., Chyla, B., Eichhorst, B., Jiang, Y., Stilgenbauer, S., Hallek, M., Fischer, K.

Get full text